drugset / Trial / NCT07398963
Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To study the safety and effectiveness of oncolytic Vaccinia VIrus-Delivered Targeted CD19 In Vivo CAR-T/M Therapy for Refractory/Relapsed B-Cell Lymphoma
Timeline
- Start
- 2026-02
- Primary completion
- 2029-07
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RGV005 | Unknown | 1e+08 unknown | Intrathecal |
| Subject | RGV005 | Unknown | 3e+08 unknown | Intrathecal |
| Subject | RGV005 | Unknown | 1e+09 unknown | Intrathecal |
| Subject | RGV005 | Unknown | 3e+09 unknown | Intrathecal |